Lingjing Xue

机构：China Pharmaceutical University · ORCID：0000-0002-6878-7853

发表论文 61 篇 · 总被引 3442 次 · h-index 27

代表论文

• Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy (2020 · Science Translational Medicine · 被引 180)
• Recognition, Intervention, and Monitoring of Neutrophils in Acute Ischemic Stroke (2019 · Nano Letters · 被引 119)
• An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques (2019 · Journal of Controlled Release · 被引 78)
• Anisamide-functionalized pH-responsive amphiphilic chitosan-based paclitaxel micelles for sigma-1 receptor targeted prostate cancer treatment (2019 · Carbohydrate Polymers · 被引 78)
• Sensitizing Tumors to Immune Checkpoint Blockage via STING Agonists Delivered by Tumor-Penetrating Neutrophil Cytopharmaceuticals (2023 · ACS Nano · 被引 76)
• Poly-β-cyclodextrin Supramolecular Nanoassembly with a pH-Sensitive Switch Removing Lysosomal Cholesterol Crystals for Antiatherosclerosis (2021 · Nano Letters · 被引 47)